Odonate Therapeutics, Inc. (ODTC) Comparison with companies in other sectors?

Odonate Therapeutics, Inc. has a share price of 1.10M. You can analyze Odonate Therapeutics, Inc. (ODTC) competitors across different market sectors through stock heatmaps.

What are ODTC's NET and operating margins?

Odonate Therapeutics, Inc. (ODTC) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does ODTC's earnings per share (EPS) trend reflect its financial momentum?

Odonate Therapeutics, Inc. (ODTC) EPS is 20580.00 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Odonate Therapeutics, Inc. is 1.07, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Odonate Therapeutics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Odonate Therapeutics, Inc. like P/E which is 8606.13, P/B which is 583.05, and PEG which is 86.06. Compare them with sector averages to evaluate if the stock is priced fairly.

Odonate Therapeutics, Inc.

ODTC•PNK

Healthcare

Biotechnology

$22005.00

$5005.00(29.44%)

Fundamental Analysis of Odonate Therapeutics, Inc. (ODTC)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$20580.00

P/E Ratio

1.07

ROE

0.07%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$24.14B

Shares OutstandingTotal number of shares issued

$1.10M

Book Value/ShareNet worth per share

$37.74

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$20580

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

7.01%

ROAReturn on total assets

6.63%

ROCEReturn on capital employed

-0.74%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$3.05

Cash/ShareCash and equivalents per share

$19.90

FCF YieldFree cash flow as percentage of market cap

0.04%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ODTCFinancial Ratios Analysis details for ODTC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ODTCSector Benchmarking details for ODTC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Odonate Therapeutics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Odonate Therapeutics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Odonate Therapeutics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Odonate Therapeutics, Inc.

For Odonate Therapeutics, Inc., essential financial indicators include EPS 20580.00, PE 1.07, and ROE 0.07. These key ratios reveal insights into Odonate Therapeutics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Odonate Therapeutics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Odonate Therapeutics, Inc.

Metrics like Net Margin - and ROA 6.63% shed light on how well Odonate Therapeutics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Odonate Therapeutics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Odonate Therapeutics, Inc.

Using ratios such as P/B Ratio 583.05 and PEG Ratio 86.06, investors can assess whether Odonate Therapeutics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Odonate Therapeutics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Odonate Therapeutics, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.02 and Cash Flow $3.05, provide a snapshot of Odonate Therapeutics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Odonate Therapeutics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Odonate Therapeutics, Inc.

Investing in Odonate Therapeutics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Odonate Therapeutics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;